|
|
||||||||
University of Pittsburgh Schools of Medicine and Pharmacy, Veterans Administration Hospital, Pittsburgh, Pennsylvania
Wistar Institute, Philadelphia, Pennsylvania
Correspondence: For reprints contact: Geoffrey Levine, PhD, Presbyterian-Univ. Hospital, Dept. of Nuclear Medicine, Pittsburgh, PA 15213.
ABSTRACT
One of the most frequent indications for patient imaging is the need to establish the presence or absence of malignant disease. Considerable effort has been invested in attempting to develop tumor-specific radiopharmaceuticals. We report the localization of an iodine-131-labeled, hybridoma-derived monoclonal antibody in the MH-15 teratocarcinoma-bearing BALB/c mouse. Tumor-to-muscle and tumor-to-blood ratios of 150:1 and 15:1, respectively, were observed at 5 days after administration of 15 µCi of labeled antibody. The relationship between the optimal imaging time and localization kinetics is discussed.
This article has been cited by other articles:
![]() |
J. Weinstein, M. Steller, A. Keenan, D. Covell, M. Key, S. Sieber, R. Oldham, K. Hwang, and R. Parker Monoclonal antibodies in the lymphatics: selective delivery to lymph node metastases of a solid tumor Science, October 28, 1983; 222(4622): 423 - 426. [Abstract] [PDF] |
||||
![]() |
J. Weinstein, R. Parker, A. Keenan, S. Dower, H. Morse 3rd, and S. Sieber Monoclonal anitbodies in the lymphatics: toward the diagnosis and therapy of tumor metastases Science, December 24, 1982; 218(4579): 1334 - 1337. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |